Sakar Healthcare Limited – Investor Presentation Summary

Key Operational Highlights

  • 69 oncology product contracts executed; 45 commercial discussions currently underway.
  • Strengthened global oncology presence in Q2 through portfolio expansion and wider market access across EU, UK, Canada, APAC and LATAM.
  • 33 tech transfer projects underway with 4 Partners; 33 site variations submitted & 11 approved across 18 cytotoxic molecules.
  • Accord received 6 more product site variations approval by EMA (total now becomes 8 of 11 molecules) at oncology site.
  • 3 other site variation approval received from MHRA / EMA (for 2-partners in UK and 1 in Germany).
  • Shared 351 dossiers globally, of which 191 have been submitted and 22 have received Marketing Authorisations.
  • Approved MAs dispersed globally: Europe & UK-11, Latin America-6, APAC-4, Canada-1.
  • 36 EU MA applications, of which 16 are own filings.
  • 21 APIs developed in-house; 16 with Written Confirmation; 8 commercialised; 2 of 7 CEP applications approved, 5 under process.
  • Commercial supplies to domestic & International Markets started from API-integrated, EU GMP-approved oncology FDF site.
  • Cancer coverage widened to breast, lung, prostate, stomach, head & neck, colorectal, ovary, liver, kidney, thyroid, blood, bone marrow and lymph.

Key drivers of operational performance: Portfolio expansion in oncology, regulatory approvals, technology transfer projects, and backward API integration.

Financial Highlights

Revenue: ₹8,741.61 lakhs (Q2 FY27)

EBITDA: ₹2,434.53 lakhs (Q2 FY27)

PAT: ₹1,130.69 lakhs (Q2 FY27)

EPS: ₹5.08 (Q2 FY27)

Margins: Gross Profit Margin 48%, EBITDA Margin 28%, PAT Margin 13%

YoY/QoQ comparison:

  • Revenue grew 52% YoY (Q2 FY26: ₹5,756.04 lakhs) and 20% QoQ (Q1 FY27: ₹7,297.25 lakhs)
  • EBITDA grew 114% YoY (Q2 FY26: ₹1,135.39 lakhs) and 15% QoQ (Q1 FY27: ₹2,124.89 lakhs)
  • PAT grew 149% YoY (Q2 FY26: ₹453.98 lakhs) and 10% QoQ (Q1 FY27: ₹1,028.49 lakhs)

H1FY27 Performance:

  • Revenue: ₹16,038.86 lakhs (45% YoY growth)
  • EBITDA: ₹4,559.42 lakhs (90% YoY growth)
  • PAT: ₹2,159.18 lakhs (134% YoY growth)
  • EPS: ₹9.70

Drivers of financial performance: Higher revenue growth, improved operational efficiency, and margin expansion.

Balance Sheet Snapshot

  • Property, Plant and Equipment: ₹32,089.98 lakhs (Sept 26) vs ₹31,905.90 lakhs (Mar 26)
  • Capital work-in-progress: ₹576.76 lakhs (Sept 26) vs ₹396.53 lakhs (Mar 26)
  • Inventories: ₹9,720.52 lakhs (Sept 26) vs ₹7,004.14 lakhs (Mar 26)
  • Trade Receivables: ₹3,940.87 lakhs (Sept 26) vs ₹5,008.33 lakhs (Mar 26)
  • Total Assets: ₹51,572.93 lakhs (Sept 26) vs ₹48,100.94 lakhs (Mar 26)

Capex & Cash Flow Health

  • Cash Flow from Operating Activities: ₹2,345.64 lakhs (H1FY27)
  • Cash Flow from Investing Activities: ₹-2,204.39 lakhs (H1FY27)
  • Cash Flow from Financing Activities: ₹-140.68 lakhs (H1FY27)
  • Net increase in Cash & Cash equivalent: ₹0.57 lakhs (H1FY27)

Strategic & R&D Initiatives

  • Investments in advanced flow chemistry (Vapourtech, UK) and GEA granulation lines
  • Green Chemistry adoption with zero-discharge systems
  • Solar systems driving sustainable manufacturing
  • 65 oncology products developed in-house with 32 ready for global launch
  • 11 bio-study completed from EMA/US FDA approved CROs

Expected impact on growth: Oncology delivers approximately 2x higher margins vs. general formulations, enhancing profitability.

Strategic Rationale: Expanding into high-growth oncology markets, reducing operational costs through vertical integration, improving supply-chain control and margin visibility.

Industry Trends & Business Environment

  • Global pharmaceutical manufacturing projected to grow from USD 549 billion in 2026 to USD 882 billion by 2031 (CAGR 9.93%)
  • India's pharmaceutical market projected to grow from USD 60.3 billion in 2026 to USD 79.7 billion by 2031 (CAGR 5.74%)
  • Global oncology drugs market valued at USD 256.46 billion in 2025, projected to grow to USD 697.59 billion by 2034
  • Rising cancer incidence with estimated 20.6 million new cases and nearly 10 million deaths annually

Impact on Company: Macro trends are driving demand for oncology treatments and creating opportunities for specialized manufacturers with regulatory compliance.

Management Commentary & Growth Outlook

Strategic Outlook: "Sakar is at crux of next phase of growth, prepared to enter the niche segment of Oncology to cater to humanity. Sakar is well equipped to deliver High Precision Research works, suitably followed by Technology Transfer and Scale-up to commercialize Anti-Cancer products worldwide." - Mr. Sanjay Shah, Chairman & MD

Risks and Opportunities: Shift towards own brand exports (70%) enhancing profitability; moving towards integrated, regulatory-driven business model.